Revenue Growth
TELA Bio reported $18.5 million in revenue for Q1 2025, marking a 12% year-over-year increase and a 5% sequential growth from Q4 2024.
Strong Product Demand
OviTex and OviTex PRS products saw significant demand, with each growing approximately 152% year-over-year.
European Market Expansion
TELA Bio's European business grew by 17% compared to Q1 2024, indicating a strong international presence.
Sales Force Effectiveness
The new territory manager and account specialist structure has been effective, with 25 new sales team members trained in 2025.
Market Leadership in Hernia Repair
TELA Bio is well positioned to capitalize on the industry's shift away from synthetic mesh, with OviTex products demonstrating strong market traction.
Innovative Product Launches
Launched larger sizes of OviTex PRS to address more complex procedures, enhancing operating room efficiency and reducing costs.
Wide Engagement with Surgeons
Presented products to over 5,000 surgeons globally through various educational and symposium events.